1)Boden WE, et al:Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503-1516, 2007
2)Task Force Members, et al:2013 ESC guidelines on the management of stable coronary artery disease;The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949-3003, 2013
3)Fihn SD, et al:2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease;A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 130:1749-1767, 2014
4)Weintraub WS, et al:Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 359:677-687, 2008
5)Al-Lamee R, et al:Percutaneous coronary intervention in stable angina(ORBITA);A double-blind, randomised controlled trial. Lancet, 2017[Equb ahead of print]
6)Patel MR, et al:ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease;A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J Am Coll Cardiol 69:2212-2241, 2017
7)IONA Study Group:Effect of nicorandil on coronary events in patients with stable angina;The Impact Of Nicorandil in Angina(IONA)randomised trial. Lancet 359:1269-1275, 2002